Physician profile
Rajeev Vasudeva
NPI 1447280128
$10,479.77
in general payments reported to CMS, 2019-2025
38 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,200 · 2020: $465 · 2021: $1,020 · 2022: $1,382 · 2023: $1,803 · 2024: $431 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,394 · Education: $18.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,393.93 |
| Education | $18.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $4,084.59 | 2019 | |
| Abbvie INC. | $2,246.60 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $768.13 | 2019-2023 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $522.73 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Qol Medical, LLC | $492.47 | 2019-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $316.82 | 2019-2025 | Entyvio |
| Merck Sharp & Dohme LLC | $242.35 | 2021-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $241.83 | 2020-2024 | Linzess |
| Celgene Corporation | $199.04 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $197.25 | 2019-2023 | |
| Pfizer INC. | $131.75 | 2019-2023 | |
| Boston Scientific Corporation | $116.56 | 2019-2023 | Advanix Biliary |
| Ferring Pharmaceuticals INC. | $115.56 | 2021-2024 | Rebyota, Clenpiq |
| Romark Laboratories, Lc | $101.78 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $73.22 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $60.16 | 2019-2025 | |
| Genzyme Corporation | $57.29 | 2023 | |
| Aimmune Therapeutics, INC. | $51.59 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $50.24 | 2023-2025 | Voquezna |
| Organon LLC | $41.59 | 2021-2023 | |
| Mylan Institutional INC. | $41.46 | 2023 | Hulio |
| Amgen INC. | $38.02 | 2023 | Amjevita, Avsola |
| Evoke Pharma, INC. | $32.60 | 2023 | Gimoti |
| Madrigal Pharmaceuticals | $32.60 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $30.42 | 2023-2024 | Ibsrela |
| Olympus America INC. | $30.25 | 2019 | |
| Fresenius Kabi USA, LLC | $23.67 | 2023 | Idacio |
| Celltrion USA INC. | $18.23 | 2024 | Zymfentra |
| Novo Nordisk INC | $16.87 | 2025 | Wegovy |
| Redhill Biopharma INC. | $16.34 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.13 | 2023 | Cyltezo |
| Alfasigma USA, INC. | $16.09 | 2020 | |
| Shire North American Group INC | $15.59 | 2019 | |
| Braintree Laboratories, INC. | $14.45 | 2022 | |
| Enterra Medical, INC. | $14.34 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $11.16 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Vasudeva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.